Skip to main content

Table 1 Basal characteristics of Isfahani adult people (n = 615) with newly thyroid function in 2011 were euthyroid in 2006

From: Incidence of thyroid dysfunction in an Iranian adult population: the predictor role of thyroid autoantibodies: results from a prospective population-based cohort study

  Euthyroid, n (%) Subclinical hypothyroidism, n (%) OR (CI 95%) Overt hypothyroidism, n (%) OR (CI 95%) Overt + subclinical hypothyroidism, n (%) OR (CI 95%) Subclinical hyperthyroidism, n (%) OR (CI 95%) Overt hyperthyroidism, n (%) OR (CI 95%) Overt + subclinical hyperthyroidism, n (%) OR (CI 95%)
Sex
 Men 281 (54.1) 27 (37.5) 1.96 (1.18–3.26)* 4 (44.4) 1.47 (0.39–5.55) 31 (38.3) 1.90 (1.17–3.07)* 2 (20) 4.7 (0.99–22.45)* 0 (0)   2 (13.3) 7.67 (1.17–34.34)*
 Women 238 (45.9) 45 (62.5) 5 (55.6) 50 (61.7) 8 (80) 5 (100) 13 (86.6)
Age (years)
 20–40 153 (29.7) 14 (19.4) 1 4 (44.4) 1 18 (22.2) 1 4 (40) 1 2 (40) 1 6 (40) 1
 40–60 274 (53.2) 42 (58.3) 1.67 (0.88–3.16) 2 (22.2) 0.27 (0.05–1.54) 44 (54.3) 1.36 (0.76–2.44) 5 (50) 0.69 (0.18–2.63) 2 (40) 0.55 (0.07–4.00) 7 (46.7) 0.65 (0.21–1.97)
 ≥60 88 (17.1) 16 (22.2) 1.98 (0.92–4.26) 3 (33.3) 1.3 (0.28–5.96) 19 (23.5) 1.83 (0.91–3.68) 1 (10) 0.43 (0.04–3.95) 1 (20) 0.86 (0.07–9.7) 2 (13.3) 0.58 (0.11–2.93)
BMI (kg/m2)
 <25 151 (29.9) 22 (31.4) 1 2 (22.2) 1 24 (30.4) 1 0 (0) 1 3 (60) 1 3 (20) 1
 25–30 230 (45.5) 27 (38.6) 0.8 (0.44–1.46) 3 (33.3) 0.98 (0.16–5.96) 30 (38.0) 0.82 (0.46–1.45) 5 (50)   1 (20) 0.21 (0.02–2.12) 6 (40) 1.31 (0.32–5.33)
 ≥30 124 (24.6) 21 (30) 1.1 (0.61–2.21) 4 (44.4) 2.43 (0.43–16.51) 25 (31.6) 1.26 (0.69–2.33) 5 (50)   1 (20) 0.40 (0.04–3.95) 6 (40) 2.43 (0.59–9.93)
FPG (mg/d)
 <100 289 (56.2) 51 (70.8) 1 7 (77.8) 1 58 (71.6) 1 7 (77.8) 1 2 (40) 1 9 (64.3) 1
 100–126 176 (34.2) 17 (23.6) 0.54 (0.3–0.97)* 1 (11.1) 0.23 (0.02–1.92) 18 (22.2) 0.51 (0.29–0.89)* 2 (22.2) 0.46 (0.09–2.28) 1 (20) 0.82 (0.07–9.12) 3 (21.4) 0.54 (0. 14–2.04)
 ≥126 49 (9.5) 4 (5.6) 0.46 (0.16–1.33) 1 (11.1) 0.84 (0.10–6.99) 5 (6.2) 0.5 (0.19–1.33) 0 (0)   2 (40) 5.8 (0.81–42.85) 2 (14.3) 1.31 (0.27–6.24)
Smoking
 Yes 42 (8.1) 4 (5.6) 0.66 (0.23–1.92) 1 (11.1) 1.42 (0.17–11.62) 5 (6.1) 0.74 (0.28–1.94) 1 (10) 1.26 (0.15–10.2) 0 (0)   1 (6.7) 0.81 (0.1–6.32)
 No 477 (91.9) 68 (94.4) 8 (88.9) 76 (93.9) 9 (90) 5 (100) 14 (93.3)
Positive family history
 Yes 132 (26.4) 29 (40.8) 1.92 (1.15–3.21)* 2 (22.2) 0.79 (0.16–3.88) 31 (38.8) 1.76 (1.07–2.88)* 7 (77.8) 9.75 (2.0–47.65)* 2 (40) 1.85 (0.30–11.24) 9 (64.3) 5 (1.65–15.24)*
 No 368 (73.6) 42 (59.2) 7 (77.8) 49 (61.3) 2 (22.2) 3 (60) 5 (35.7)
TPOAb (IU/mL)
 Positive 110 (23.4) 27 (42.2) 2.39 (1.39–4.11)* 4 (50) 3.2 (0.8–13.33) 31 (43.1) 2.48 (1.46–4.14)* 8 (80) 13.12 (2.74–62.72)* 4 (80) 13.12 (1.45–118.6)* 12 (80) 13.12 (3.63–47.35)*
TgAb (IU/mL)
 Positive 3 (9.4) 2 (25) 3.22 (0.43–23.65) 1 (100) 0 3 (33.3) 4.83 (0.77–30) 0 (0)   0 (0)   0 (0)  
  1. BMI body mass index, FPG fasting plasma glucose, TPOAb Thyroid peroxidase antibody, as considered positive when level >75 IU/mL, TgAb thyroid globulin antibody as considered positive when level >100 IU/mL, CI confidence interval
  2. * P value <0.05
Back to article page

European Journal of Medical Research

ISSN: 2047-783X

Contact us